Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation

LORENZUTTI AUGUSTO MATÍAS; LITTERIO NICOLÁS JAVIER; AGUILAR SOLEDAD; DE LUCAS BURNEO JOSÉ JULIO; RUBIO-LANGRE SONIA; SAN ANDRÉS MANUEL IGNACIO

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2018

0140-7783

In llama crias (tekes), Escherichia coli and Staphylococcus aureus are major pathogens, and marbofloxacin could be a suitable choice. The objectives of this study were (i) to evaluate the serum pharmacokinetics of marbofloxacin (5 mg/kg) after intravenous administration in tekes and simulate a multidose regimen; (ii) to emulate pharmacokinetic profiles after single dose and steady-state conditions by Monte Carlo simulation (iii) to determine the MIC of regional strains of Escherichia coli and Staphylococcus aureus; (iv) to perform a PK/PD analysis by Monte Carlo simulation. Pharmacokinetics of marbofloxacin was evaluated in six animals at 3, 10, 24, 50 and 80 days after birth. Marbofloxacin were determined by HPLC. A steady-state multi-dose simulation was carried out, and concentration-time profiles were generated by Monte Carlo simulation. MIC of marbofloxacin against regional E. coli and S. aureus strains were also determined. Finally, a PK/PD analysis was conducted by Monte Carlo simulation. After pharmacokinetic analysis, clearance showed a trend to increase (0.14 and 0.18 L*Kg-1*h-1), and AUC (36.74 and 15.21 µg*h/mL) and Vss (3.06 and 3.37 L/Kg) trended to decrease at 3 and 80 days-old respectively, showing accumulation ~50% in animals with 3 days. All strains tested of E. coli (MIC90=0.06 µg/mL) and S. aureus (MIC90=0.25 µg/mL) were susceptible to marbofloxacin. PK/PD analysis suggests that the therapeutic regimen of marbofloxacin could be effective for infections caused by E. coli strains in animals between 3-80 days, with a CFR for Cmax/MIC>10 of 100% and for AUC24/MIC>125 of 99.99%; and for infections produced by S. aureus in animals between 3-24 days-old, with a CFR for Cmax/MIC>10 of 93.08% and for AUC24/MIC>60 of 97.01%, but a higher dose should be used in older animals, because PK/PD endpoints were not met.